GenSight Biologics
Update in progressSIGHT.PA (Paris)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
GenSight Biologics S.A. is a Paris-based clinical-stage biotechnology company developing therapies for neurodegenerative retinal diseases and CNS disorders. It uses gene therapy with mitochondrial targeting sequences and optogenetics. Lead candidates are LUMEVOQ, an AAV2 gene therapy in Phase III for Leber hereditary optic neuropathy due to ND4 mutations, and GS030, in Phase I/II for retinitis pigmentosa and dry AMD. Preclinical programs exist. It collaborates with multiple academic and industry partners. Incorporated 2012.
Company score
- Sentiment
- 0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.41
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.15
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketParis (PAR)
- LocationFrance
- CEOMs. Laurence Rodriguez
- Founded2012
- Employees13
- Websitewww.gensight-biologics.com
Identifiers
- ISINFR0013183985